earnings
NV
NYSE · NVS
Novartis AG
Healthcare · Drug Manufacturers - General
$138.62
Down-$0.37 (-0.27%)
Updated Sep 16, 2026, 8:46 AM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 258.98B
- P/E ratio
- 18.18
- Dividend yield
- 2.88%
- 52-week range
- $121.57 – $170.46
- Volume
- 2.37M
- Avg. volume
- 1.65M
Price performance
NVS price history
1M range · 20 trading sessions · Daily adjusted prices
NVS closed at $138.62 after 20 trading sessions, down 10.31% for the selected period.
- Last close
- $138.62
- Period change
- -10.31%
- Period low
- $137.16
- Period high
- $163.09
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $138.76 | $139.11 | $137.37 | $138.62 | 2.37M |
| Sep 14, 2026 | $141.64 | $141.64 | $138.99 | $138.99 | 2.48M |
| Sep 11, 2026 | $139.31 | $139.55 | $137.00 | $137.16 | 2.35M |
| Sep 10, 2026 | $138.76 | $139.43 | $137.46 | $137.48 | 2.42M |
| Sep 9, 2026 | $138.14 | $139.45 | $137.30 | $137.48 | 2.94M |
| Sep 8, 2026 | $139.94 | $140.46 | $137.115 | $137.70 | 10.27M |
| Sep 4, 2026 | $159.90 | $160.93 | $159.625 | $159.99 | 1.29M |
| Sep 3, 2026 | $164.48 | $164.48 | $161.42 | $163.09 | 2.45M |
| Sep 2, 2026 | $160.80 | $163.18 | $160.38 | $162.46 | 4.34M |
| Sep 1, 2026 | $162.15 | $163.57 | $160.21 | $161.25 | 4.33M |
| Aug 31, 2026 | $152.60 | $152.74 | $151.685 | $152.06 | 1.29M |
| Aug 28, 2026 | $154.51 | $154.565 | $152.77 | $153.81 | 1.17M |
| Aug 27, 2026 | $155.925 | $155.93 | $154.43 | $154.65 | 1.22M |
| Aug 26, 2026 | $158.41 | $159.19 | $157.44 | $157.54 | 1.47M |
| Aug 25, 2026 | $158.51 | $160.29 | $157.83 | $159.98 | 998.18K |
| Aug 24, 2026 | $157.12 | $158.46 | $156.77 | $158.02 | 801.26K |
| Aug 21, 2026 | $156.17 | $159.715 | $156.10 | $158.86 | 1.18M |
| Aug 20, 2026 | $159.07 | $159.33 | $155.87 | $156.24 | 1.53M |
| Aug 19, 2026 | $156.29 | $160.81 | $156.17 | $160.31 | 2.4M |
| Aug 18, 2026 | $153.58 | $155.10 | $153.38 | $154.55 | 1.41M |
Latest NVS news
The latest Smart Investors Daily articles mentioning NVS.
Stock researchCompany · Overview
NVS research
Overview
Company profile and research snapshot.
Company profile
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $127.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Sell | — |
| Jul 13, 2026 | BERENBERG | Hold | — |
| Jul 9, 2026 | ARGUS RESEARCH CORPORATION | Buy | — |
| Jun 30, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.